Nektar Therapeutics Cash Flow - Quarterly (NASDAQ:NKTR)

Add to My Stocks
$18.79 $0.6 (3.09%) NKTR stock closing price Apr 26, 2017 (Closing)

The financial analysis of NKTR requires an investor to check the cash flows for Nektar Therapeutics. The profit-loss statement shows Nektar Therapeutics profits, the balance sheet shows Nektar Therapeutics debt, and the cash flow statement reflects the liquidity and solvency of a firm. This statement reflects the company's ability to generate cash flows. Nektar Therapeutics had cash and cash equivalents of $55.57M at beginning of quarter and $59.64M at quarter end for 2016-Q4. Nektar Therapeutics cash flow analysis tells whether or not the company has enough cash for its day to day activities, and for investing for future growth. Nektar Therapeutics saw a outflow of $142.1M from investing activities for 2016-Q4. View details of Nektar Therapeutics cash flows for latest & last 40 quarters.

show more
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec. 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3
Nektar Therapeutics Net Income Cash Flow
Depreciation Depletion Amortization Cash-Flow15.35M11.5M7.63M3.71M12.85M9.1M5.83M2.97M12.92M9.73M
Net Increase (Decrease) in Assets Liabilities7.93M26.01M16.47M-12.12M-34.7M6.23M18.44M21.19M-116.42M-60.81M
Cash From (used in) Discontinued Operations----------
Other Adjustments Net13.21M9.19M6.74M4.25M29.94M13.72M10.61M5.32M15.4M-58.06M
Nektar Therapeutics Net Cash from (used by) Operating Activities
Increase (Decrease) in Prop Plant And Equipment-6.39M-3.74M-3.23M-1.67M-11.19M-8.72M-4.58M-1.05M-9.97M-6.09M
Acquisition Disposition of Subsidiaires----------
Increase (Decrease) in Investments-76M63.44M34.55M37.92M-28.14M-23.4M-8.25M54.21M-27.59M-6.67M
Other Cash Inflow (Outflow) from Investment Activities----25M25M----
Nektar Therapeutics Net Cash from (used by) Invesment Activities
Issuance (Purchase) of Equity Shares209.56M18.04M9.64M6.09M32.2M15.51M7.79M1.68M163.52M132.7M
Issuance (Repayment) of Debt Securities-5.94M-5.37M-3.51M-1.72M98.57M-3.79M-2.48M-1.09M-3.53M-2.57M
Increase (Decrease) in Bank & Other Borrowings----------
Payment of Dividends & Other Cash Distributions----------
Other Cash from (used by) Financing Activities---------7M-7M
Nektar Therapeutics Net Cash from (used by) Financing Activities
Effect of Exchange Rate Changes on Cash-0.12M-0.03M-0.09M0.01M-0.15M-0.15M-0.02M0.03M-0.1M-0.04M
Nektar Therapeutics Net Change in Cash & Cash Equivalents
Cash & Equivalents at Beginning of Year55.57M12.36M39.06M25.43M15.31M17.75M49.59M155.58M76.29M63.76M
Cash & Equivalents at Year End59.64M63.29M55.67M72.54M55.57M18.81M20.87M129.45M12.36M32M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters
Get Cash flow for another ticker

The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Nektar Therapeutics stock price history and Nektar Therapeutics stock comparison chart inevitably reflect its cash flow situation.
  • Net Change in Cash and Cash Equivalents: Nektar Therapeutics cash reduced QoQ to $-153.52M, meaning the company is unable to meet its expenditure and grow cash which will also eventually reflect in the Nektar Therapeutics stock price movement.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-117.02M for NKTR.
  • Growth companies (typically most tech companies) spend heavily  on investing activities and this figure was negative at $-82.4M for NKTR stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Cash Flow from financing activities: Financing activities include the cash that comes into a company in the form of loans or interest earned or shareholders money, as well as the cash that goes out. Nektar Therapeutics earned $190.95M from financing activities,in the form of repayment of loans or interest paid, dividend pay-out to shareholders etc.

Key Financial Ratios For Nektar Therapeutics Cash Flow

FCF margin